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ABSTRACT  
Purpose: To investigate the association between the GABAergic drugs, benzodiazepines or 
zopiclone, and the occurrence of asthma exacerbations and subsequent mortality in a cohort 
of asthma patients.  
Methods: 105,747 patients without asthma exacerbation and 25,895 patients with 
exacerbated asthma were included. A nested case-control study probed the association 
between benzodiazepines or zopiclone and occurrence of asthma exacerbation (primary 
outcome) using conditional logistic regression. Cox regression was used to determine the 
association between the drugs and all-cause mortality in patients with recorded asthma 
exacerbation. Adjusted matched odds ratios (adj mOR), and adjusted hazard ratios (adj HR) 
with 95% confidence intervals (CI) are presented. 
Results: Current benzodiazepine use was associated with increased occurrence of asthma 
exacerbation (adj mOR 1.49; 1.15-1.93; P=0.001) as was current zopiclone use (adj mOR 
1.59; 95% CI 1.37-1.85; P<0.001). In patients with an asthma exacerbation, current 
benzodiazepine use was associated with increased all-cause mortality during a median 
follow-up of 2 years (adj HR 2.78; 95% CI 1.26-6.12; P=0.011), and the association between 
zopiclone use and all-cause mortality showed borderline statistical significance (adj HR 1.58; 
95% CI 0.98-2.54; P=0.058).  
 Conclusion: Benzodiazepines and zopiclone may increase the likelihood of asthma 
exacerbation and benzodiazepines may also increase the likelihood of mortality following 
exacerbation. These data suggest that caution should be exercised when prescribing 
benzodiazepines to patients with asthma.  
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INTRODUCTION   
Asthma affects 235 million people globally
1
 with estimated mortality of 1.1 and 1.6 per 100, 
000 patients per year in the United States (US)
2
 and the United Kingdom (UK)
3
 respectively. 
One potentially important strategy to reduce this burden of disease is to identify modifiable 
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risk factors, including medications that predispose to exacerbation of asthma and subsequent 
mortality.  
Benzodiazepines are widely prescribed especially for the treatment of anxiety and insomnia,
4
 
through modulation of inhibitory Ɣ-amino butyric acid Type A (GABAA) receptors in the 
brain.
5
 Occasionally they may also be used in treatment of severe anxiety that presents during 
asthma attacks.
6
 However they are not innocuous; accumulating evidence suggest they may 
cause harm
7, 8
, including increased mortality in the general population
9
 and risk of cancer.
10
 
Benzodiazepines may also increase the risk from infection.
11-13
 Obiora et al found that 
benzodiazepine exposure in the community was associated with an increased risk of 
pneumonia and subsequent all-cause mortality following pneumonia.
14
 Meta-analysis of data 
from randomised controlled trials for non-benzodiazepine GABAergic hypnotics (zopiclone, 
ramelteon, zaleplon and zolpidem) also identified an increased risk of infection (risk ratio; 
1.44, 95% confidence interval 1.25-1.64, p < 0.001).
15
 These data support evidence from 
critical care where benzodiazepine sedation is associated with increase in mortality in septic 
patients relative to non-GABAergic sedation.
16
 However, the data are somewhat inconsistent 
overall, with two studies
17, 18
 suggesting a protective effect on pneumonia and some finding 
no statistical association.
19-21
 With regards to all-cause mortality, a systematic review 
conducted in 2009 found mixed and inconclusive results.
22
 Thus, further data are urgently 
required.   
In asthma, increased expression of epithelial GABAA receptors leads to the overproduction of 
mucus.
23
 Furthermore, allergen-induced asthma in mice increases the expression of 
benzodiazepine-sensitive GABAA receptors on alveolar macrophages.
13
 Augmented 
GABAergic signalling, such as through benzodiazepine treatment, impairs immune responses 
through intracellular acidosis of monocytes and macrophages, leading to increased mortality 
in animal models of infection
13, 24
 supporting the observations in humans.
9, 14
 Given the 
Copyright © 2015 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2015; 24: 793–802DOI: 10.1002/pds 
3 
 
intrinsic role of the pulmonary GABAergic system in the pathogenesis of asthma and 
accumulating data on potential harms of benzodiazepines especially from infections, we have 
evaluated GABAergic drugs in asthmatic patients in relation to the occurrence of asthma 
exacerbations, and mortality following asthma exacerbation.  
METHODS 
Data source 
Data were extracted from the Clinical Practice Research Datalink (CPRD) that contains the 
medical records of over 13 million patients prospectively collected from over 600 general 
practices across the UK. CPRD has demonstrated a high level of completeness of clinical, 
diagnostic and prescription data according to validation studies.
25
 This electronic database is 
linked to other data sources for example hospital patient records (the Hospital Episode 
Statistics database [HES] and national death registry data (the Office of National Statistics 
[ONS]) which were utilised in this study (CPRD: http://www.cprd.com/). 
Sampling frame 
People with a diagnosis of asthma (n=225,543[Appendix 1]) were identified using relevant 
diagnostic codes (Read codes [Appendix3]) which map on to the international classification 
of disease (ICD-9) codes, for the study period 01/01/2005 through 31/12/2011.  
Outcome definition  
The primary outcome for the nested case-control analysis was physician diagnosed asthma 
exacerbation (cases), identified using Read codes. We used hospital data to identify missing 
patients using the ICD 10 code for status asthmaticus (J46)/or a record of hospitalisation 
occurring within 14 days of a primary care diagnosis of asthma exacerbation. The date of the 
first recorded diagnosis of asthma exacerbation during the study period was designated the 
index date. All asthma patients, in the study population, who had not experienced an 
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exacerbation during the study period, were identified as potential controls. These were 
individually matched to cases by age at index date (±3 years), sex and general practice 
(matching on general practice i.e. primary care clinic, was performed to account for 
differences in prescribing policies and patient management followed in various primary care 
clinical settings). A maximum of six controls were matched to each case to give sufficient 
sample size for stratified analyses. The sample size was calculated using the Dupont Power 
and Sample size program (Appendix 2).
26
  The secondary outcome of interest was all-cause 
mortality (over a median follow-up time of 1.97 years) following a diagnosis of asthma 
exacerbation during the study period, investigated using survival analysis, including only 
those patients diagnosed with an asthma exacerbation (Appendix 1).  
Exposure definition 
Data were extracted for all recorded prescriptions of benzodiazepines and zopiclone. The 
most recent prescription prior to the asthma exacerbation diagnosis date (or the index date of 
the matched case for controls) was retained. Benzodiazepines were considered both as a class 
and as individual drugs. The three most frequently used individual benzodiazepines in the 
study population, namely, diazepam, temazepam and lorazepam were also identified for a 
priori stratified analyses, representing long-acting, intermediate and short-acting agents 
respectively. Exposure was considered current when the most recent prescription was within 
the 30 days prior to the index date. The most commonly prescribed oral benzodiazepines in 
the UK typically have a 20-28 tablet pack-size.
4
 We used this to reason that long-term regular 
users of benzodiazepines would have repeat monthly prescriptions from their general 
practitioner. Presence of a repeat prescription defined long term drug use whereas the absence 
of it was considered short term use. Prescriptions in the period 31 to 90 days and >90 days 
before index date were classified as recent and past exposures respectively. No evidence of 
prescribing at any point in the patient’s past primary care records defined ‘never’ users. 
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Potential confounders  
A validated weighted, comorbidity index (Charlson’s comorbidity index) was adopted as a 
measure of comorbidity burden.
27
 In addition, we adjusted for depression, sleeping problems, 
psychosis, stress and anxiety, identified as important confounders in previous related studies
9, 
14
 but not covered by the Charlson index. Other potential confounders considered included 
age, sex, current smoking (most recent record), alcohol consumption (measured as units of 
alcohol consumed per week and categorised according to the UK weekly recommended 
alcohol consumption limits; <14units/week for women and <21units/week for men), 
socioeconomic status (measured using Index of Multiple deprivation (IMD) score quintiles)
28
 
and body mass index (as recorded by general practitioners and categorised according to 
WHO guidelines).
29
 Current exposures (as defined previously) to statins, opioids, beta-2 
agonists and topical respiratory corticosteroids (oral, inhaled, nasal and nebulised) were also 
considered.  
Statistical analyses 
Conditional logistic regression was used to investigate the association between drug exposure 
and asthma exacerbation. Cox regression modelling was used to assess the association 
between drug exposure and mortality following asthma exacerbation after checking that 
proportional hazards assumptions were met. Missing data were included in the analysis as 
dummy variables. 
We constructed two multivariable models for each exposure variable: Model 1 included all 
covariates that were significantly associated with both asthma exacerbation and the exposure 
variable (p<0.05) and Model 2 included all potential confounders as listed in the previous 
section.  We tested for interaction with comorbidities and where a statistically significant 
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interaction was found the multivariable analysis was repeated, stratified by the interaction 
variable categories.  
To quantify the proportion by which the incidence of asthma exacerbation among asthma 
patients would reduce if exposure to benzodiazepines was eliminated,
30
 the adjusted 
attributable fraction (AF) among the exposed and the adjusted population attributable fraction 
(PAF) were determined using the user-generated package ‘punaf’ in Stata.31, 32 We also 
calculated the unadjusted number needed to harm (the inverse of the absolute risk increase).
30
 
All statistical analyses were conducted in Stata version 12.  
RESULTS  
Characteristics of study participants 
A total of 131,642 patients were included in the main analysis after excluding patients with 
anomalies in key dates e.g. registration and death dates (Appendix 1). Of these, 
60,542(57.25%) were females, 32,311(30.56%) were aged below 18 years and 
25,895(19.67%) had an asthma exacerbation of which nearly 8% (2,063) were severe. 
Benzodiazepine exposure was noted in 20,725 patients, comprising 15.74% of the study 
population overall. Patients with asthma exacerbation were more likely to be from more 
deprived settings, have a diagnosis of depression, be current smokers, overweight or obese 
and have had a prescription of corticosteroids, opioids and beta-2 agonists (Table 1). 
Table 1: Characteristics of asthma patients with and without asthma exacerbation 
(n=131,642) 
                                                                  Exacerbation of asthma 
Characteristic  No (n=105747)% Yes (n=25895) % Crude OR (95% CI) P Value 
Age (years)     
<18 32311 (30.56) 7945 (30.68) †  
18-44 37089(35.07) 8640(33.37)   
45-65 24595(23.26) 6200 (23.94)   
>65 11752 (11.11) 3110(12.01)   
Gender      
Male  45205 (42.75) 10821(41.79) †  
Female  60542(57.25) 15074(58.21)   
IMD score quintiles     
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1 (least deprived)  13898(13.14) 2990 (11.55) 1  
2 14001 (13.24) 3478 (13.43 ) 1.18(1.11-1.26) P trend < 0.001 
3 12390 (11.72) 3018 (11.65) 1.18(1.10-1.26)  
4 12750(12.06) 3219(12.43) 1.25(1.16-1.33)  
5 (most deprived) 11884(11.24) 3014(11.64) 1.29(1.20-1.39)  
Missing  40824(38.61) 10176(39.30) -  
Current smoking     
No 63522 (60.07) 17260 (66.65) 1  
Yes 16720(15.81) 4753 (18.35) 1.12(1.08-1.17) < 0.001 
Missing  25505(24.12) 3882(14.99) -  
Alcohol 
consumption 
    
≤ alcohol weekly 
limit 
31262 (29.56) 8011 (30.94) 1  
> alcohol weekly 
limit 
3953 (3.74) 943(3.64 ) 0.93(0.86-1.00) 0.059 
Missing  70532(66.70) 16941 (65.42) -  
Anxiety      
No  104433(98.76) 25446(98.27) 1  
Yes  1314(1.24) 449(1.73) 1.38(1.24-1.55) <0.001 
Stress      
No 105275(99.55) 25734(99.38) 1  
Yes  472(0.45) 161(0.62) 1.40(1.16-1.68) <0.001  
Depression      
No   92720 (87.68) 21786(84.13) 1  
Yes  13027 (12.32) 4109 (15.87) 1.34(1.29-1.40) < 0.001 
Psychosis      
No  105418 (99.69) 25788(99.59) 1  
Yes  329 (0.31) 107(0.41) 1.28(1.02-1.61) 0.030 
Sleeping problems     
No 99123(93.74) 23671(91.41) 1.00  
Yes 6624(6.26) 2224(8.59) 1.38(1.31-1.46) <0.001 
Charlson’s 
Comorbidity  index 
score 
    
0 91472(86.50) 21776(84.09) 1  
1-2 11189(10.58) 3286(12.69) 1.20(1.15-1.26) P trend < 0.001 
3-5 2710(2.56) 773(2.99) 1.13(1.03-1.24)  
>5 376(0.36) 60(0.23) 0.60(0.45-0.79)  
BMI     
Normal weight 24013(22.71) 5733(22.14) 1  
Underweight 1679(1.59) 410(1.58) 0.94(0.84-1.06) P trend < 0.001 
Overweight 19429(18.37) 5292(20.44) 1.17(1.12-1.22)  
Obesity  16195 (15.31) 5306(20.49) 1.41(1.35-1.47)  
Missing  44431(42.02) 9154(35.35) -  
Corticosteroids 
(nasal, oral, inhaled 
and nebulised)
¶
 
    
No  104024(98.37) 23430(90.48) 1  
Yes  1723(1.63) 2465(9.52) 6.32(5.91-6.75) < 0.001 
Opioids
¶
      
No  105394(99.67) 25746(99.42) 1  
Yes  353(0.33) 149(0.58) 1.65(1.35-2.02) < 0.001 
Beta-2-agonists
¶     
No  103468(97.8) 23042(88.98) 1  
Yes  2279(2.16) 2853(11.02) 5.61(5.28-5.95) < 0.001 
Statins
¶
      
No  105321(99.60) 25779(99.55) 1  
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Yes  426(0.40) 116(0.45) 1.02(0.82-1.26) 0.858 
†Matching variables 
Statistically significant results are highlighted in bold 
¶Drug prescriptions within 30 days prior to index date 
 
Benzodiazepines and occurrence of asthma exacerbation 
Table 2 shows results for the association between benzodiazepines and zopiclone and asthma 
exacerbation. After adjustment for all variables (Model 2), anytime exposure to 
benzodiazepines was statistically significantly associated with increased occurrence of 
asthma exacerbation (adj mOR 1.29; 95% CI 1.23-1.35; P<0.001). When only current use of 
benzodiazepines was considered, the point estimate increased for occurrence of asthma 
exacerbation (adj mOR 1.49; 95% CI 1.15-1.93; P=0.001). Similarly, current zopiclone use 
was associated with increased occurrence of asthma exacerbation (adj mOR 1.59; 95% CI 
1.37-1.85; p<0.001). On considering individual benzodiazepines, the occurrence of asthma 
exacerbation was elevated for current use of diazepam and temazepam. However, the 
association between current lorazepam and asthma exacerbation lacked statistical 
significance. Duration of benzodiazepine use did not alter the observed association with 
asthma exacerbation with both long- and short-term users at risk (Table 2). Statistically 
significant interactions were found with Charlson’s comorbidity index score. Table 3 shows 
the stratified analysis results. The association between anytime benzodiazepine use and 
asthma exacerbation was stronger among asthma patients without comorbidities.  
 
Using unadjusted risks, we estimated that over a one year follow-up period, the number 
needed to harm was 22 (95% CI 12-109), indicating that for every 22 asthma patients 
prescribed benzodiazepines annually, one additional asthma exacerbation could be expected. 
Moreover, in asthma patients prescribed benzodiazepines (20,725 Patients), 4.2% of all 
asthma exacerbations were attributable to benzodiazepines (adjusted AF 4.23; 95% CI 3.54, 
4.92). An adjusted PAF of 3.39 (95% CI 2.83, 3.94) suggests that 3.4% of asthma 
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exacerbations in all asthma patients could be reduced if use of benzodiazepines was 
eliminated.  
Table 2: Association of benzodiazepines/zopiclone exposure with asthma exacerbation 
Exposure  Controls 
(n=105747)% 
Cases 
(n=25895)% 
 OR (95% CI)
†
 Adjusted models  OR (95% CI) 
    Model 1 Model 2 
Benzodiazepines      
Never   90156(85.26) 20761(80.17) 1.00 1.00 1.00 
Ever  15591(14.74 ) 5134(19.83) 1.46(1.40-1.52) 1.26(1.21-1.31) 1.29 (1.23-1.35) 
BZD timing       
Non- use 90156 (85.26) 20761(80.17) 1 1.00 1.00 
Current 238(0.23) 97(0.37) 1.78(1.39-2.27) 1.51(1.18-1.94) 1.49(1.15-1.93) 
Recent  415(0.39) 151(0.58) 1.63(1.34-1.97) 1.39(1.14-1.69) 1.36(1.11-1.66) 
Past  14938(14.13) 4886(18.87) 1.45(1.39-1.51) 1.25(1.20-1.30) 1.28(1.23-1.34) 
 BZD  duration       
Non-use  90156(85.26) 20761(80.17) 1.00 1.00 1.00 
Short-term 14453(13.67) 4786(18.48) 1.46(1.41-1.53) 1.27(1.21-1.32) 1.30(1.24-1.35) 
Long-term  1138(1.08) 348(1.34) 1.37(1.21-1.56) 1.15(1.01-1.31) 1.17(1.02-1.33) 
Diazepam      
Never    95806(90.60) 22479(86.81) 1.00 1.00 1.00 
Ever  9941(9.40) 3416(13.19) 1.47(1.41-1.54) 1.31(1.25-1.37) 1.33(1.27-1.40) 
Diazepam timing ǂ      
Current  164(0.16) 62(0.24) 1.64(1.21-2.21) 1.38(1.01-1.87) 1.42(1.04-1.94) 
Recent  289(0.27) 107(0.41) 1.60(1.27-2.01) 1.39(1.10-1.76) 1.35(1.06-1.71) 
Past  9488(8.97) 3247(12.54) 1.47(1.40-1.53) 1.30(1.24-1.36) 1.33(1.27-1.40) 
Temazepam       
Never 101774(96.24) 24666(95.25) 1.00 1.00 1.00 
Ever 3973(3.76) 1229(4.75) 1.23(1.15-1.32) 1.05(0.98-1.13) 1.07(0.99-1.15) 
Temazepam 
timing ǂ  
     
Current  41(0.04) 25(0.10) 2.39(1.42-4.01) 2.13(1.25-3.62) 1.93(1.10-3.38) 
Recent  87(0.08) 28(0.11) 1.28(0.82-2.00) 1.09(0.69-1.70) 1.10(0.70-1.74) 
Past  3845(3.64) 1176(4.54) 1.22(1.14-1.31) 1.04(0.96-1.12) 1.06(0.98-1.14) 
Lorazepam       
Never 105339(99.61) 25770(99.52) 1.00 1.00 1.00 
Ever  408(0.39) 125(0.48) 1.26(1.03-1.55) 1.08(0.88-1.34) 1.11(0.90-1.38) 
Lorazepam  
timing ǂ 
     
Current  9(0.01) 1(0.00) 0.48(0.06-3.81) 0.47(0.06-3.86) 0.48(0.06-3.96) 
Recent  15(0.01) 8(0.03) 2.33(0.97-5.60) 1.97(0.82-4.74) 2.29(0.96-5.47) 
Past  384(0.36) 116(0.45 1.24(1.00-1.54) 1.06(0.86-1.32) 1.08(1.05-1.60) 
Zopiclone       
Never  99401(94.00) 23662(91.38) 1.00 1.00 1.00 
Yes  6346(6.00) 2233(8.62) 1.50(1.42-1.58) 1.26(1.19-1.33) 1.28(1.21-1.36) 
Zopiclone       
Non- use 99401(94.00) 23662(91.38) 1.00 1.00 1.00 
Current  645(0.61) 295(1.14) 1.91(1.65-2.20) 1.57(1.35-1.82) 1.59(1.37-1.85) 
Recent  364(0.34) 135(0.52) 1.60(1.30-1.96) 1.31(1.06-1.62) 1.34(1.08-1.65) 
Past  5337(5.05) 1803(6.96) 1.44(1.36-1.53) 1.22(1.14-1.29) 1.24(1.16-1.32) 
 
Note: BZD refers to benzodiazepines; statistically significant results are highlighted in bold 
ǂ reference group is benzodiazepines never users; † adjusted for age, sex and general practice (matching variables);  Model 1 
adjusted for  age, sex, general practice, Charlson’s comorbidity index score, sleep disorders, stress, anxiety, depression, 
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psychosis, opioids, alcohol, current smoking, body mass index and multiple deprivation score; Model 2: Model 1 covariates, 
beta 2 agonists, statins and corticosteroids. 
  
Table 3: Association of asthma benzodiazepines and asthma exacerbation stratified by 
Charlson’s comorbidity score   
 
 
 
Note: ¥Reference group is ‘non benzodiazepine users’  
†adjusted for age, sex, general practice, sleep disorders, stress, anxiety, depression, psychosis, opioids, beta 2 agonists and 
corticosteroids alcohol, current smoking, body mass index and multiple deprivation score statins 
Statistically significant results are highlighted in bold 
× could not be calculated due to insufficient data 
 
Benzodiazepines and mortality following asthma exacerbation 
Table 4 presents HRs for the association between benzodiazepines or zopiclone exposures 
and all-cause mortality subsequent to asthma exacerbation over the study period (median 
follow-up 1.97 years). Benzodiazepine use was found to be significantly associated with 
increased mortality following asthma exacerbation (adj HR 1.32; 95% CI 1.08-1.61; p=0.006) 
with current and recent prescriptions associated with the greatest effect. Individually, only 
diazepam was significantly associated with increased mortality over the study period (adj HR 
1.27; 95% CI 1.01-1.59; P=0.037). However, the sample sizes were insufficient to fully 
investigate the individual effects of other benzodiazepines on mortality. The unadjusted 
number needed to harm (NNH) was estimated as 17(95% CI 9 - 133); thus for every 17 
asthma patients taking benzodiazepines, one additional death could be expected within a 
median follow-up time of 2 years.  The association between current zopiclone use and all-
Exposure variable  Adjusted mOR
† stratified by Charlson’s comorbidity index (CCI) score   
 CCI score 0 CCI score 1-2 CCI score 3-5 CCI score >5 
Benzodiazepines      
No 1.00 1.00 1.00  
Yes 1.36(1.29-1.43) 1.24(1.08-1.43) 1.04(0.72-1.49) 
x 
Benzodiazepines 
¥
     
Current  1.60(1.18-2.19)  0.63(0.25-1.55) 
x x 
Recent  1.45(1.13-1.85) 1.68(0.82-3.41) 
x x 
Past  1.35(1.28-1.43) 1.25(1.08-1.44) 
x x 
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cause mortality following asthma exacerbation showed borderline statistical significance (adj 
HR 1.58; 95% CI 0.98-2.54; P=0.058). 
Table 4: Association between benzodiazepines/zopiclone use and all-cause mortality 
following asthma exacerbation in all ages (n=25887) 
 
Drug Numbers 
dead (%) 
(n=459) 
Unadjusted model 
HR(95% CI) 
Adjusted models 
HR
1 
(95% CI) 
 
   Model 1 Model 2 
Benzodiazepines      
Never  272(1.31) 1.00 1.00 1.00 
Ever 187(3.64) 3.14(2.61-3.79) 1.33(1.09-1.63) 1.32(1.08-1.61) 
Benzodiazepines     
Non-use 246(1.31) 1.00 1.00 1.00 
Current 6(7.22) 6.21(2.93-13.16) 2.69(1.24-5.82) 2.78(1.26-6.12) 
Recent 6(5.30) 5.24(2.59-10.58) 3.38(1.64-6.94) 3.40(1.65-6.98) 
Past 158(3.52) 3.02(2.50-3.66) 1.27(1.04-1.56) 1.26(1.03-1.54) 
Diazepam       
Never 353(1.57) 1.00 1.00 1.00 
Ever  106(3.10) 2.25(1.81-2.80) 1.28(1.02-1.60) 1.27(1.01-1.59) 
Temazepam      
Never 403(1.63) 1.00 1.00 1.00 
Ever  56(4.56) 3.02(2.28-3.40) 1.14(0.85-1.53) 1.14(0.85-1.52) 
Lorazepam      
Never 453(1.76) 1.00 1.00 1.00 
Ever  6(4.80) 3.42(1.53-7.66) 1.61(0.72-3.63) 1.61(0.72-3.63) 
Zopiclone      
Never  385(1.63) 1.00 1.00 1.00 
Ever  74(3.31) 2.39(1.86-3.06) 1.17(0.89-1.53) 1.16(0.88-1.51) 
Zopiclone timing      
Non-use 385(1.63) 1.00 1.00 1.00 
Current  19(6.44) 4.58(2.89-7.27) 1.60(1.00-2.57) 1.58(0.98-2.54) 
Recent  5(3.70) 2.86(1.18-6.92) 1.64(0.67-4.04) 1.68(0.68-4.19) 
Past  50(2.77) 1.99(1.48-2.67) 1.03(0.75-1.41) 1.02(0.74-1.39) 
 
-Model 1: Adjusted for age, gender, Charlson’s comorbidity index score, sleep disorders, anxiety, stress, depression, 
psychosis, opioids, steroids, statins, beta2agonists, alcohol consumption, current smoking, body mass index and Index of 
Multiple Deprivation 
-Model 2: Adjusted for all the factors in model 1 as well as steroids, statins and beta2agonists that failed to reach statistical 
significance (p<0.05) in univariate analysis for asthma exacerbation and benzodiazepines.   
-Statistically significant results are highlighted in bold                                                                                                                                                                                                                                                                                                               
 
Sensitivity Analyses 
As benzodiazepines and other GABAergic drugs are commonly used as hypnotics and 
anxiolytics in adults,
33, 34
 we conducted a sensitivity analysis restricted to study subjects aged 
18 years and older. The results from this sensitivity analysis for the association of 
benzodiazepines and asthma exacerbation were similar to the original ones (sensitivity 
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analysis results: adj mOR 1.28; 95% CI 1.22, 1.33; P<0.001; original results: adj mOR 1.29; 
95% CI 1.23, 1.35; P<0.001).  
To minimise bias from misclassification of asthma exacerbation, corticosteroid prescribing 
was considered a proxy indication of an asthma exacerbation. A sensitivity analysis 
excluding controls with a current steroid prescription, (1723[1.63%]), yielded similar results 
to the original ones (sensitivity analysis results: adj mOR 1.29; 95% CI 1.23, 1.34; P<0.001, 
original results: adj mOR 1.29; 95% CI 1.23, 1.35; P<0.001)). In addition, an attempt was 
made to quantify missed exacerbations as determined from CPRD-HES linked data; 0.44% 
(287) of the exacerbations were recorded in HES but not in CPRD. A sensitivity analysis 
undertaken using only HES linked data (64,832 patients) yielded comparable results to the 
original ones (sensitivity analysis results: adj mOR 1.25; 95% CI 1.18, 1.33; P<0.001, 
original results: adj mOR 1.29; 95% CI 1.23, 1.35; P<0.001).  
Severity of disease may influence disease outcome including all-cause mortality. However, 
only 0.1% (128) of the sample had severe asthma. A subgroup analysis excluding these 
patients yielded no change in our results for the occurrence of asthma exacerbation 
(sensitivity analysis results: adj mOR 1.29; 95% CI 1.23, 1.34; P<0.001 original results: adj 
mOR 1.29; 95% CI 1.23, 1.35; P<0.001). In addition, hospitalised exacerbations, considered 
as a proxy measure for severe asthma exacerbation in this study, were only found in 2063 
(7.97%) patients with asthma exacerbation. A subgroup analysis excluding these patients 
yielded comparable mortality results to original ones (subgroup analysis results: adj HR 1.40; 
95% CI 1.12, 1.75; p=0.001, original results (adj HR 1.32; 95% CI 1.08, 1.61; p=0.006).   
 
 DISCUSSION 
Summary of main findings 
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The findings of this study suggest that use of benzodiazepines and zopiclone is associated 
with increased occurrence of asthma exacerbation and 2-year mortality after exacerbation; a 
heightened likelihood of exacerbation associated with current use increases biological 
plausibility. The high prevalence of asthma as a disease and, of benzodiazepines exposure 
(15.7%) in this representative cohort, suggests our findings have public health significance.  
 
Strengths and limitations 
To our knowledge, this is the first epidemiological study to examine benzodiazepine use and 
the occurrence of asthma exacerbation and subsequent mortality. Use of the CPRD database 
has enhanced the generalisability of these findings and also allowed adequately powered 
analyses. Data on drug exposures are collected prospectively, prior to asthma exacerbation, 
thus eliminating any recall bias. Moreover, reporting bias is virtually eliminated as data are 
routinely collected, prospectively by general practitioners during patient consultation for 
patient care and medico-legal record-keeping. Using cohort data eliminates any temporal 
biases relating to timing of exposure. A conditional logistic regression was performed with 
cases and controls individually matched on age, sex, and general practice and further 
adjustment for a wide range of potential confounders including Charlson’s comorbidity index 
score
27
 and other specific diseases identified as confounders of the relationship between 
benzodiazepines and disease outcomes (sleeping problems, anxiety, stress, psychosis and 
depression).
9, 14
 In addition, the effect of other drugs that could be concurrently prescribed 
with benzodiazepines (e.g. opioids) and other factors that may trigger an asthma exacerbation 
(e.g. smoking) were controlled for. The data on important confounders like smoking and 
alcohol are usually gathered in primary care, especially for patients presenting with alcohol-
related and smoking-related disease, in response to the introduction of incentive payments in 
2004 by the Quality Outcomes Framework.
35
 However, the inherent limitations of 
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observational studies using routine databases to deal with confounding should also be 
recognised, in particular residual and unmeasured confounders (for example nutritional and 
physical factors which are not routinely recorded in CPRD). Read codes were used to identify 
disease variables, therefore variations in coding practices in different general practices, could 
have led to misclassification of asthma exacerbation. This is likely to be a non-differential 
bias that if it occurred, would have shifted the effect size towards unity. To minimise 
misclassification bias, corticosteroid prescribing was considered a proxy indication of an 
asthma exacerbation however this sensitivity analysis did not affect the results. Care was also 
taken to avoid multiple counting of a single asthma exacerbation (i.e. multiple consultations 
for the same episode) by analysing only the first documented asthma exacerbation in the 
study period.  
The use of prescription data does not allow any assessment of compliance with treatment. 
Whilst this could lead to misclassification of exposure, the effects are likely to be non-
differential and would therefore bias results towards unity. Nevertheless, the observed 
associations still remained when we assessed chronic benzodiazepine use as indicated by 
repeat prescriptions (Table 2). 
 
Our calculations suggest that benzodiazepines may account for nearly 3.4% of exacerbations 
in asthma patients and that one additional asthma exacerbation would be triggered within a 
year of using benzodiazepines for every 22 asthma patients. In addition, our findings suggest 
that for every 17 asthma patients taking benzodiazepines, one additional death could be 
expected within a median follow-up time of 2 years. However, these results should be 
interpreted with caution as the NNH estimates are based on unadjusted risks; and while the 
PAF has been calculated using adjusted risk estimates, both measures assume a causal 
relationship that an observational study such as this cannot establish. Moreover, our study did 
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not assess drug dosages. Future studies should look at drug dosages and frequency in greater 
detail.  
 
Comparison with existing literature 
It is not possible to make a direct comparison of the results from our study with earlier 
findings as ours is the first study we are aware of that directly assesses benzodiazepines effect 
in asthma patients. Recently a similar observation has been made for patients with chronic 
obstructive pulmonary disease where benzodiazepines increased outpatient exacerbations and 
visits to the emergency room.
8
 Obiora et al also found that benzodiazepines were associated 
with an increased risk of pneumonia and pneumonia-related mortality in a non-selected 
population.
14
 Results for both benzodiazepines as a class and individual benzodiazepines are 
in line with those from the current study. In both studies, the highest risks were observed in 
relation to current use of benzodiazepines, particularly diazepam. The diazepam finding may 
be attributable to its prolonged half-life and active metabolites.
36
 However we suspect that the 
non-significant association observed for other individual benzodiazepines with mortality 
could be due to relatively low usage in the population studied and that this is in fact a drug 
class effect.  
 
It is also interesting to note that patients with a lower comorbidity burden were at increased 
risk of worse outcome from benzodiazepines similar to previous observations with 
pneumonia.
14, 37
 We surmise that the presence of comorbidity reduces the proportion of risk 
attributable to benzodiazepine exposure in the individual patient. 
 
Our observation that benzodiazepine, and zopiclone exposure, are associated with an 
increased odds of asthma exacerbation is biologically plausible given the role of GABAA 
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receptor signalling in the pathogenesis of asthma
23
 and immunity in the lung.
13
  While 
epidemiological studies cannot prove a causal relationship between benzodiazepines and 
asthma exacerbations, a large well-conducted epidemiological study can detect adverse drug 
effect signals that may be missed in the average randomised controlled drug trial.
38
 Ideally, a 
large RCT should be conducted to investigate this association (for the outcome of 
‘exacerbations’) ethical considerations permitting; alternatively, additional evidence from 
large prospective cohort studies, using standardised data collection protocols and self-
controlled case series that would account for fixed confounding via intra-person 
comparisons,
39
 could strengthen the existing evidence. 
CONCLUSION 
Benzodiazepines are prescribed in up to one-sixth of patients with asthma. This study shows 
that these drugs along with zopiclone may increase the risk of asthma exacerbation; the risk 
of mortality after exacerbation may also be increased. Caution should be exercised when 
prescribing benzodiazepines in patients with asthma. 
 
Key points  
• A high prevalence of benzodiazepines use (15.7%) was found in the asthma cohort studied.  
• Having been prescribed a benzodiazepines within 30 days prior, was associated with an 
approximately 50% increased likelihood of asthma exacerbation. 
• The non-benzodiazepine hypnotic, zopiclone, which also works via activation of GABAA 
receptors, was associated with a similar increase in the likelihood of asthma exacerbation. 
• Both benzodiazepines and zopiclone were also found to be associated with increased 
mortality in the 2 years after an asthma exacerbation. 
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Appendices   
Appendix 1 Asthma study subject selection procedure 
 
 
                   
                   
                   
                   
             
                   
           
 
 
 
 
 
           
 
 
 
 
 
 
225543 patients met all the inclusion criteria 
 1240150 had an event record with 
specified asthma diagnosis codes 
 1208773 met CPRD  quality control 
standards (acceptable patients) 
 1208728 met gender criteria  (male 
and female only) 
 264998 patients with event records 
such that at least one event occurs 
within study period (01/01/2005 - 
31/12/2011) 
 225543 patients met all the above 
criteria  
 
27652 Patients with asthma 
exacerbation 
 
 1757 patients excluded  
 
Reasons for exclusion: 
 146 patients  with index 
dates before first 
registration dates  
 5 patients with index dates 
after  death dates  
 35 patients with index dates 
after  transferred out of the 
practice dates  
 1571 patients with no 
matched control 
 
197891 Patients without asthma
exacerbation  
 
 
25895 Patients with asthma 
exacerbation 
 
 
92144 excluded 
for not getting 
a matched case 
 
 
105747 patients without asthma 
exacerbation matched to cases 
on age, sex and practice 
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Appendix 1 continued  
 
 
 
 
 
  
 
  
 
 
131642 patients included in the 
logistic regression model to 
investigate the association between 
benzodiazepines/zopiclone and 
asthma exacerbation 
 
 
 
25887 patients included in the 
Cox regression model to 
investigate the association 
between BZPs/zopiclone and 
mortality subsequent to 
exacerbation of asthma 
 
 
 
8 patients excluded 
Reasons for exclusion: 
 2 patients with death dates 
on the same date as they 
transferred out of the 
practice  
 5 patients with death dates 
on last date of data 
collection at the practice 
 1 patient with death date 
before asthma exacerbation 
date 
 
 
64832 patients had HES-CPRD 
linked data utilised in sensitivity 
analyses to cater for missed 
exacerbations while using data 
from only CPRD 
 
 
 
14133 patients 
had an 
exacerbation of 
asthma: 
 287 
exacerbations  
in only HES 
 11979 
exacerbations 
in only CPRD  
 1867 
exacerbations 
in both CPRD 
and HES 
 
 
 
 
 
2063 Patients had an 
exacerbation of asthma 
requiring hospitalisation 
which was used as a proxy 
measure for severe asthma 
exacerbation 
 
 
 
 
 
 
Over all total deaths: 
459 
 282 deaths identified 
from ONS data 
 239 deaths in both 
CPRD and ONS data 
 43 deaths in only 
ONS data 
 416 deaths identified 
from CPRD data 
 
 
 
105747 patients without asthma 
exacerbation matched to cases 
on age, sex and practice 
 
 
25895 Patients with asthma 
exacerbation 
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Appendix 2: Sample size calculation  
 
1. Nested case-control study 
Outcome measure Probability of 
benzodiazepine 
use in controls 
Odds ratio 
(cases v. 
Controls) 
Cases 
needed 
Controls 
needed 
Outcome 
measure 
Asthma 
exacerbation 
0.17
1
 2.00
2
 119 714 
Asthma 
exacerbations 
requiring 
hospitalisation 
0.17 1.50 378 2268 
2. Cohort study 
Outcome measure 
 
Ratio of 
unexposed to 
exposed 
Hazard ratio 
(unexposed 
v. Exposed) 
Exposed  
patients 
Unexposed 
patients 
 mortality 3 1.2 718 2154 
 a. Calculated using the Dupont Power and Sample size program as described in Dupont WD, Plummer WD: "Power and 
Sample Size Calculations: A Review and Computer Program", Controlled Clinical Trials 1990; 11:116-28.  
b. Standard assumptions: 
Powered at 80% with a type 1 error probability of 0.05, ratio of control to cases 6:1 (case-control analysis) 
Correlation coefficient for exposure between matched cases and controls assumed to be 0.2 based on recommendations in 
Dupont (1988)26 
Median survival time in unexposed cases assumed to be 6 years (based on previous work in this topic area) with the ratio of 
unexposed to exposed subjects 3:140 
1 Probability of benzodiazepine use in controls based on population prevalence derived from The Health Improvement 
Network (THIN), a primary care database 
2 Based on previous point estimates obtained when investigating the association between benzodiazepine use and pneumonia 
incidence in THIN 
 
 
 
Appendix 3: Readcodes for asthma  
Asthma  
Readcode Read term   
H33..00 Asthma   
H33zz00 Asthma NOS   
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H33..11 Bronchial asthma   
H33z.00 Asthma unspecified   
H330.00 Extrinsic (atopic) asthma   
H330.12 Childhood asthma   
H331.00 Intrinsic asthma   
H331.11 Late onset asthma   
H33z200 Late-onset asthma   
H330000 Extrinsic asthma without status asthmaticus   
H332.00 Mixed asthma   
H334.00 Brittle asthma   
H331z00 Intrinsic asthma NOS   
H331000 Intrinsic asthma without status asthmaticus   
 
Exacerbation of asthma 
Readcode Read term   
H333.00 Acute exacerbation of asthma   
H33z100 Asthma attack   
H33z011 Severe asthma attack   
H33z000 Status asthmaticus NOS   
H330111 Extrinsic asthma with asthma attack   
H33z111 Asthma attack NOS   
H330100 Extrinsic asthma with status asthmaticus   
H331111 Intrinsic asthma with asthma attack   
H331100 
Intrinsic asthma without status 
sthmaticus   
  
Asthma exacerbation requiring hospitalisation 
Readcodes   Read term 
8H2P.00      Emergency admission, asthma 
663m.00     Asthma accident and emergency attendance since last visit 
663d.00      Emergency asthma admission since last appointment 
 
 
